A Phase 4 interventional study of voriconazole in Infections, Fungal, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-10-14.
Sponsored by Pfizer · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing voriconazole in Mycoses — none open to participants now, none under way, none of them phase 3. Voriconazole · Mycoses.
Among the 17 studies testing voriconazole in Mycoses, this one is the 15th largest by enrollment, is the only one that started in 2007, is one of 4 in phase 4, and was the 7th registered.
260 studies on the registry are indexed under Mycoses; 37 are open to participants now.
Browse Mycoses studies →None of the 17 studies testing voriconazole in Mycoses is open now. The open studies under Mycoses, anywhere →
Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 24 Mycoses studies recruiting now, 13 (54%) set no upper age limit and 4 (17%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2007.
This study's enrollment of 12 is below the median of 68 across 164 interventional studies indexed under Mycoses.
Median enrollment 29 across the 17 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
10 studies in Mycoses by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 5 (50%) have results posted.
Among the 10 studies in Mycoses by Pfizer, this one is the only one that started in 2007, is one of 2 in phase 4, and was the 6th registered.
Pfizer’s Mycoses studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing voriconazole in Mycoses, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 10 in Mycoses:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the amount of voriconazole in the brain after 2 loading doses and 3 maintenance doses over 3 days and compare it to the amount of voriconazole in the plasma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
voriconazole twice daily
Drug: voriconazole
Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
Also known as: Vfend
Plasma Concentrations of Voriconazole
Mean plasma voriconazole concentrations (nanograms per milliliter \[ng/mL\]) pre-dose (Cmin) and two hours post-dose (C2h). Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.
Time frame: Day 3: pre-dose, 2 hours post-dose
Brain Concentrations of Voriconazole
Mean brain concentrations (ng/mL) of voriconazole pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).
Time frame: Day 3: pre-dose, 2 hours post-dose
Plasma Concentrations of N-oxide Metabolite
Mean plasma concentrations of voriconazole N-oxide metabolite (ng/mL) pre-dose and 2 hours post-dose. Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.
Time frame: Day 3: pre-dose, 2 hours post-dose
Brain Concentrations of N-oxide Metabolite
Mean brain concentrations (ng/mL) of voriconazole N-oxide metabolite pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).
Time frame: Day 3: pre-dose, 2 hours post-dose
Healthy male volunteers were recruited by 1 hospital center in the U.S. between March 2007 and August 2008.
| Milestone | Voriconazole |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
Mean plasma voriconazole concentrations (nanograms per milliliter \[ng/mL\]) pre-dose (Cmin) and two hours post-dose (C2h). Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.
| ng/mL | Voriconazole |
|---|---|
| predose (Cmin) | 839.50 ± 874.22 |
| 2 hours postdose (C2h) | 2182.33 ± 1190.63 |
Mean brain concentrations (ng/mL) of voriconazole pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).
| ng/mL | Voriconazole |
|---|---|
| predose (Cmin) | 2090.44 ± 1227.88 |
| 2 hours postdose (C2h) | 4165.20 ± 1806.93 |
Mean plasma concentrations of voriconazole N-oxide metabolite (ng/mL) pre-dose and 2 hours post-dose. Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.
| ng/mL | Voriconazole |
|---|---|
| predose (Cmin) | 3076.67 ± 841.96 |
| 2 hours postdose (C2h) | 3665.00 ± 958.73 |
Mean brain concentrations (ng/mL) of voriconazole N-oxide metabolite pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).
| ng/mL | Voriconazole |
|---|---|
| predose (Cmin) | 663.97 ± 677.55 |
| 2 hours postdose (C2h) | 1535.40 ± 1280.09 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole | — | 0/12 (0%) | 11/12 (91.7%) |
| Event | Voriconazole |
|---|---|
| PhotophobiaEye disorders | 5/12 |
| HeadacheNervous system disorders | 4/12 |
| Vision blurredEye disorders | 3/12 |
| Dry mouthGastrointestinal disorders | 2/12 |
| Procedural dizzinessInjury, poisoning and procedural complications | 2/12 |
| DizzinessNervous system disorders | 2/12 |
| Head discomfortNervous system disorders | 2/12 |
| Ear discomfortEar and labyrinth disorders | 1/12 |
| Dry eyeEye disorders | 1/12 |
| Abdominal painGastrointestinal disorders | 1/12 |
| Age, Customized(participants) | Voriconazole |
|---|---|
| 18-25 years | 3 |
| 26-35 years | 6 |
| 36-45 years | 3 |
| Sex: Female, Male(Participants) | Voriconazole |
|---|---|
| Female | 0 |
| Male | 12 |
The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole